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Abstract 
Paraneoplastic opsoclonus is well described
in neuroblastoma. In the adult oncologic popu-
lation,  opsoclonus  is  seen  usually  within  the
context of opsoclonus–myoclonus ataxia and is
associated  most  strongly  with  small-cell  lung
cancer. Patients with paraneoplastic opsoclonus
are often seronegative. Patients with gynecolog-
ic malignancies are known to be predisposed to
paraneoplastic  syndromes;  however,  we
describe the first case of paraneoplastic opso-
clonus in association with endometrial cancer.
Introduction
Gynecologic  malignancies  are  capable  of
causing  neurologic  changes  through  non-
metastatic paraneoplastic effects. The develop-
ment  of  cerebellar  degeneration  in  patients
with ovarian cancer, often associated with the
measurable emergence of the PCA-1 (anti-Yo)
antibody, perhaps is the most frequently cited
example of this phenomenon. To the best of
our knowledge, we report the first case of opso-
clonus as a suspected paraneoplastic manifes-
tation of endometrial cancer.
Opsoclonus refers to involuntary, conjugate,
multivectorial, saccadic eye movements. It can
occur as an isolated neurologic anomaly but,
when  it  occurs  with  involuntary  multifocal
jerking  movements  of  the  skeletal  muscula-
ture,  the  phenomenon  is  known  as  opso-
clonus–myoclonus syndrome (OMS). The syn-
drome  often  includes  features  of  ataxia,  or
incoordination with voluntary movements. In
the setting of malignancy, opsoclonus is linked
most clearly to neuroblastoma, occurring in 3%
of childhood cases. Anti-neuronal antibodies,
usually  to  nuclear  antigens,  are  considered
markers of immune system activation in this
disorder, detected in 81% of pediatric patients.
However,  the  relationship  between  the  anti-
bodies and the appearance of the syndrome is
unclear as 25% of those children with neuro -
blastoma without neurological symptoms may
be found with the same antibodies. As is fre-
quently seen with other paraneoplastic neuro-
logical syndromes,  opsoclonus–myoclonus  in
the setting of neuroblastoma most often occurs
in the setting of limited-stage disease. In the
adult  oncologic  population,  opsoclonus–
myoclonus ataxia is associated most strongly
with small-cell lung cancer and breast cancer,
often  also  associated  with  anti-neuronal
nuclear  antibodies,  especially  ANNA-2  (anti-
Ri).
1,2 Other adult tumor types linked to this
syndrome include non-small-cell lung cancer,
3
melanoma,
4,5 sarcoma,
6 and  non-Hodgkin’s 
lymphoma.
7 A thorough search of the medical
literature uncovered no reports of paraneoplastic
opsoclonus,  with  or  without  detectable  auto  -
antibodies, in endometrial cancer patients.
Case Report
A 65-year-old woman presented with several
months  of  increasing  abdominal  girth.  The
clinical  examination  showed  ascites,  and
abdominal imaging revealed omental caking.
Cytology tests of paracentesis fluid were nega-
tive,  but  a  biopsy  of  a  peritoneal  nodule
revealed  metastatic  serous  carcinoma  of
Müllerian origin. CA-125 was measured at 171
U/mL.  She  was  referred  to  the  Mayo  Clinic,
where she had an exploratory laparotomy with
a total abdominal hysterectomy, bilateral sal  -
pingo-oophorectomy,  lymphadenectomy,  and
omentectomy. The pathological examination of
the  uterus  revealed  an  invasive  FIGO
(Fédération  Internationale  de  Gynécologie
Obstétrique)  grade  III  (of  III)  endometrial
adeno  carcinoma  of  mixed  serous-endometri-
oid  types,  arising  in  an  endometrial  polyp
(Figure  1).  There  was  no  invasion  into  the
myometrium. Both ovaries and Fallopian tubes
were  pathologically  normal.  Intraoperatively,
there was no evidence of carcinomatosis but
the omentum appeared enlarged and inflamed;
omental biopsies revealed high-grade papillary
serous carcinoma. One pelvic lymph node, of
53 pelvic and seven para-aortic nodes sampled,
was positive for metastatic disease. The clin  -
ical, imaging, and pathological features were
consistent with stage IV endometrial cancer. 
Two weeks prior to her surgical debulking,
the  patient  experienced  the  acute  onset  of
involuntary  eye  movements  and  oscillopsia
that  quickly  rendered  her  unable  to  walk.
Within a week of her first symptoms, she was
wheelchair-bound and keeping her eyes closed
almost constantly even during wakefulness to
avoid “bouncing vision”. Although she had ini-
tially  reported  a  non-specific  dizziness,  this
complaint  also  worsened  after  seven  to  ten
days and she developed vertiginous sensations
with a clear rotational component but no tin  -
nitus or hearing loss. An otolith-repositioning
maneuver on the right side did not produce
any lasting improvement in her visual or gait
disturbances.  She  could  not  identify  any
antecedent  infectious  symptoms.  The  only
prior neurologic history was that of pseudo-
claudication from lumbar spinal stenosis. On
neurologic examination, low-amplitude high-
frequency ocular flutter and square-wave jerks
were evoked by vertical gaze, and similar but
larger-amplitude  and  lower-frequency  move-
ments were seen in both directions with sus-
tained lateral gaze. Pupillary light responses
were preserved. Funduscopy was normal. The
remainder  of  the  cranial  nerve  examination
was normal. Gait was abnormal, in excess of
her baseline difficulties with osteoarthritis of
the  knees  and  pseudoclaudication,  primarily
consistent  with  ataxia.  Mild  incoordination
was also observed with hand movement. 
Her  work-up  included  magnetic  resonance
imaging of the brain, which showed no signal
abnormality or abnormal enhancement in the
cerebellum, brain stem, or elsewhere. A serum
paraneoplastic  autoantibody  evaluation  for
muscle and neuronal AChR, P/Q and N-type volt-
age-gated calcium channels, neuronal voltage-
gated K
+ channels, ANNA-1, ANNA-2, ANNA-3,
AGNA-1,  PCA-1,  PCA-2,  PCA-Tr,  amphiphysin,
and CRMP-5 IgG was completely negative. CSF
analysis was not performed. Within a week post-
operatively, her neurologic symptoms began to
recede with resolution of her upper extremity
incoordination  as  well  as  dramatic  improve-
ment  of  her  involuntary  eye  movements  and
vertiginous  symptoms.  Within  three  weeks
postoperatively,  during  which  time  she  had
been  transferred  to  a  rehabilitation  hospital,
she could rise from a chair independently and
her  gait  had  improved  to  the  point  that  she
could proceed 16 steps with the use of a walker.
After five weeks of postoperative recovery and
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two doses of carboplatin/paclitaxel chemother -
apy, with a decline in her CA-125 to 10 U/mL, the
patient had improved to the point that her opso-
clonus was only barely visible during saccadic
testing and she was able to rise from a wheel-
chair  and  climb  on  to  an  examination  table
under her own power. Five months later, she
had complete resolution of her opsoclonus and
ataxia, ambulating without a cane or walker. 
Discussion
The primary goal in treating paraneoplastic
autoimmunity is to remove the inciting anti-
gen. While OMS often can be a monophasic
process outside of the context of an associated
malignancy,  spontaneous  remission  of  para  -
neoplastic neurologic disorders is uncommon;
complete or partial neurologic recovery seems
to occur only with treatment of the underlying
tumor.
8 Although  the  serum  paraneoplastic
autoantibody evaluation was negative for pre-
viously described markers of cancer-associated
autoimmunity, as has been true in many docu-
mented reports, it nonetheless remains likely
that this patient’s condition was immunologic  -
ally mediated. It is postulated that opsoclonus
is caused by interference with premotor omni-
pause neurons in the brainstem
9 but the pre-
cise  pathophysiology,  especially  as  it  might
relate  to  an  autoimmune  mechanism,  is
unclear. Rapid improvement in immunologic  -
ally mediated nervous system disorders typic  -
ally is associated with antibody-mediated phe-
nomena, especially for neuromuscular disor-
ders. For central nervous system disease, the
mechanism  for  antibody-mediated  pathology
and its reversibility with therapy has not been
clearly delineated.  
To our knowledge, this is the first report of
opsoclonus  in  association  with  endometrial
cancer.  There  are  no  established  markers  to
identify  adult  patients  with  paraneoplastic
opsoclonus–myoclonus but the patient’s neuro-
logic symptoms rapidly abated and ultimately
resolved  altogether  following  surgical  and
chemotherapeutic interventions for her stage
IV disease. The temporal alignment between
the  improvement  in  her  neurologic  function
and the treatment of her cancer strongly sug-
gests a paraneoplastic phenomenon. A review
of the English-language literature reveals three
cases of OMS in association with ovarian neo-
plasms, and all three patients’ neurologic symp-
toms were ameliorated by anti-neoplastic ther-
apy: a 15-year-old with a mature teratoma and a
negative  paraneoplastic  panel,  whose  symp-
toms  improved  after  surgery;
10 a  45-year-old
with epithelial ovarian carcinoma and negative
PCA-1, ANNA-1, and ANNA-2 antibodies, whose
neurologic status improved after surgery and
chemotherapy;
11and a 58-year-old with anaplas-
tic  adenocarcinoma  of  the  ovarian  duct  and
seropositivity  for  ANNA-2,  whose  symptoms
improved  after  surgery,  although  she  also
received  steroids.
12 Taken  together,  our  case
plus these published accounts would indicate
that  some  antigen(s)  within  the  Müllerian
epithelium  can  incite  an  immune  response
that may elicit a reversible targeted dysfunction
of an inhibitory component of the brainstem
oculomotor system. To date, however, there is
no  identifiable  common  denominator  among
the various gynecologic malignancies and para-
neoplastic neurologic disorders.
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Case Report
Figure  1.  High  power  view  of  grade  III
endometrial  adenocarcinoma,  mixed
serous and endometrioid types, arising in
an  endometrial  polyp.  There  was  no
myometrial invasion detected.